scholarly journals STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE

2019 ◽  
Vol 18 (5) ◽  
pp. 54-60
Author(s):  
A. N. Stukov ◽  
S. F. Vershinina ◽  
N. A. Koziavin ◽  
T. Yu. Semiglazova ◽  
L. V. Filatova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Transgenic Mice ◽  
Tumor Growth ◽  
Growth Inhibition ◽  
Growth Index ◽  
Tumor Growth Inhibition ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Her 2 ◽  
Positive Breast Cancer

Because of the high risk of brain metastases from HER2-positive breast cancer, the study of the anticancer activity of drugs used to treat brain tumors, in particular lomustine, is of great importance. In the FVB/N Her-2 transgenic mice bearing HER2-positive breast cancer (BC HER2+), a single oral administration of lomustine at a dose of 50 mg/kg resulted in a significant tumor growth inhibition (up to 96 %, p<0.0001). The tumor growth index (TGI) expressed as a ratio between the areas under the kinetic curves of tumor growth in the study and control groups and amounted to 33 % (p<0.001) indicated the high activity of lomustine. However, the effect of lomustine on intramuscularly transplanted Ehrlich tumor was insignificant (tumor growth inhibition and tumor growth index were <39 % and 68 %, respectively). Lomustine administered orally at a single dose of 50 mg/kg 24 hours after intracranial transplantation of BC HER2+ increased the median survival time up to 30 days in FVB/N mice compared to 21 days in the control group mice (p<0.001). The high therapeutic effect of lomustine in HER2-positive breast cancer mice is likely can be explained by the biological characteristics of this tumor; therefore clinical trials of lomustine for HER2-positive tumors are needed.

EFFECT OF METFORMIN, MELATONIN AND THEIR COMBINATIONS WITH PACLITAXEL ON THE GROWTH OF TRANSPLANTABLE HER2-POSITIVE BREAST TUMOR IN FEMALE FVB/N MICE

2017 ◽  
Vol 63 (4) ◽  
pp. 650-654
Author(s):  
Mikhail Osipov ◽  
Tatyana Semiglazova ◽  
Irina Popovich ◽  
Andrey Panchenko ◽  
Margarita Tyndyk ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Growth Inhibition ◽  
Treatment Efficacy ◽  
Breast Tumor ◽  
Cytotoxic Effect ◽  
Growth Index ◽  
Mammary Adenocarcinoma ◽  
Tumor Growth Inhibition ◽  
Her2 Positive ◽  
Subcutaneous Inoculation

69 female FVB/N mice were used. After subcutaneous inoculation of tumor cells of transplantable HER2-positive mammary adenocarcinoma all animals were randomly divided into 7 groups and received metformin 100 mg /kgdaily, melatonin 10 mg/kg daily, paclitaxel 6 mg/kg once a week as a monotherapy or in combination. Treatment efficacy was assessed by tumor growth inhibition and the tumor growth index. It was shown that melatonin increased the cytotoxic effect of pacli-taxel whereas monotherapy with metformin led to statistically significant tumor growth inhibition

scholarly journals Enchancement of Toremifene Anti-Tumor Action by Metformin and Unusual Side Effect of Toremifene in Male Transgenic Mice with HER2-Positive Breast Tumor

Drug Research ◽  
2019 ◽  
Vol 69 (12) ◽  
pp. 683-687
Author(s):  
Alexander N. Stukov ◽  
Mikhail A. Osipov ◽  
Tatjana Y. Semiglazova ◽  
Larisa V. Filatova ◽  
Valerij A. Alexandrov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Kinetic Curve ◽  
Cancer Model ◽  
Gland Tumor ◽  
Her2 Positive ◽  
Intact Control ◽  
Breast Cancer Model ◽  
Her 2 ◽  
Positive Breast Cancer

AbstractHER2-positive breast tumors are found in 25–30% of patients with breast cancer and are characterized by aggressive course and reduced sensitivity to both chemotherapy and hormone therapy. The aim of the work was to study the possibilities of enhancing the therapeutic effect of anti-estrogen drug toremifene by combining it with biguanide, metformin, on the HER2-positive breast cancer model in FVB/N HER-2/neu transgenic mouse. Male FBV/N mice with intramuscularly transplanted HER2-positive mammary gland tumor from a female mouse of the same strain have been given toremifene (30 mg/kg, orally daily) or metformin (100 mg/kg, orally daily) that had a moderate antitumor effect (decrease the area under the kinetic curve of tumor growth by 1.6 and 1.5 times, respectively, when compared with intact control). Co-administration of these drugs in the same doses had a more pronounced effect (the area under the kinetic curve of tumor growth decreased by 3.1 times compared to intact control; p<0.05). After 10 days, in group receiving toremifene all 10 mice developed inguinal-scrotal hernias, and in group that received toremifene plus metformin - only 5 of 10 (p=0.0325). By the 15th day after the start of treatment, the hernias was also determined in all mice treated with the combination of toremifene and metformin, but the size of the hernial sac was significantly smaller than in those receiving only toremifene - 537 ± 96 mm3 and 1309 ± 120 mm3, respectively (p=0.0001). A possible explanation is the manifestation of collagen-degrading effect of toremifene.

scholarly journals Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Cancers ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 342 ◽  
Author(s):  
Babak Nami ◽  
Hamid Maadi ◽  
Zhixiang Wang
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Molecular Mechanisms ◽  
Growth Factor Receptor ◽  
Breast Cancers ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Her 2 ◽  
Available Information ◽  
Positive Breast Cancer

Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as adjuvant therapy in combination with docetaxel to treat metastatic HER2-positive breast cancer. Adding the monoclonal antibodies to treatment regimen has changed the paradigm for treatment of HER2-positive breast cancer. Despite improving outcomes, the percentage of the patients who benefit from the treatment is still low. Continued research and development of novel agents and strategies of drug combinations is needed. A thorough understanding of the molecular mechanisms underlying the action and synergism of trastuzumab and pertuzumab is essential for moving forward to achieve high efficacy in treating HER2-positive breast cancer. This review examined and analyzed findings and hypotheses regarding the action and synergism of trastuzumab and pertuzumab and proposed a model of synergism based on available information.

Treatment outcomes among human epidermal growth factor receptor 2 positive breast cancer patients: A systematic review

2021 ◽  
pp. 107815522110055
Author(s):  
Amsalu Degu ◽  
Asha Yussuf
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Treatment Outcomes ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Her 2 ◽  
Positive Breast Cancer

Background The incidence of human epidermal growth factor receptor 2 (HER 2) positive breast cancers is rapidly rising worldwide. Although there have been many studies on HER 2 breast cancer treatment and management in recent years, there is a lack of comprehensive reports on the treatment outcomes and disparities within the available literature. Hence, this review aimed to determine the treatment outcomes and their associated factors among patients with HER2-positive breast cancer. Methods A computer-based systematic literature search was conducted using PubMed, EMBASE, and Google scholar databases of articles published from 2000 to 2020. The following key terms (HER 2 positive breast cancer, predictor, determinant, associated factor) and Medical Subject Headings (MeSH) terms (breast neoplasms, treatment outcome, and risk factors) were used to search the English language published articles. Results In most studies, trastuzumab was the most commonly used treatment regimen used in combination with chemotherapeutic agents. Generally, most of the studies (15 studies) showed that the overall survival outcome was relatively higher after treatment among HER2 positive breast cancer patients. Nonetheless, two studies showed that the absence of significant change in the overall survival despite adequate treatment was given to the study participants. In addition, three studies demonstrated a partial response after treating HER2-positive breast cancer patients. Conclusion Generally, the overall survival outcome was relatively higher after treatment among HER2 positive breast cancer patients. The addition of trastuzumab in most of the studies has shown improvement in the overall survival and the disease-free survival rate of the study patients.

Sign in / Sign up

Export Citation Format

Share Document